REG - SkinBioTherapeutics - Notice of Results

SkinbiotherapeuticsAnnouncement

26/11/2021 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211126:nRSZ7803Ta&default-theme=true

RNS Number : 7803T  SkinBioTherapeutics PLC  26 November 2021

26 November 2021

 

SkinBioTherapeutics plc

 

Notice of Results

 

SkinBioTherapeutics plc's (AIM: SBTX or the "Company") financial results for
the twelve months to 30 June 2021 will be released on Tuesday 30 November
2021. The annual report and financial statements will be available on the
Company's website (https://www.skinbiotherapeutics.com/) following release to
the London Stock Exchange.

 

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                 Tel: +44 (0) 161 468 2760

 Stuart J. Ashman, CEO

 Doug Quinn, CFO
 Cenkos Securities Plc (Nominated Adviser & Broker)      Tel: +44 (0) 20 7397 8900

 Giles Balleny, Max Gould (Corporate Finance)

 Michael Johnson, Dale Bellis (Sales)
 Instinctif Partners (financial press)                   Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Nathan Billis                    SkinBio@instinctif.com (mailto:SkinBio@instinctif.com)

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AsixBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis was launched on 29 October - World
Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For
more information, visit: www.skinbiotix.com (http://www.skinbiotix.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBLBDBBBDDGBL